Brief

The inspection of AD NUCLEIS' establishment in Grézieu La Varenne (Rhône) revealed significant non-conformities and shortcomings. These were notified to the company in a letter prior to injunction on January 10, 2025, with additional information provided on May 9, 2025. The inspection highlighted several areas of concern, including incomplete data for device descriptions and specifications, conception and fabrication details, risk management, performance studies, stability studies, labeling, and equipment maintenance. The ANSM has issued injunctions to AD NUCLEIS to address these issues within specified timeframes, ranging from 3 to 12 months. The company is required to complete documentation, provide data on device design and manufacturing, establish a risk management plan, conduct performance validation, update labeling and notices, ensure equipment maintenance, and guarantee traceability. Failure to comply may have significant implications for the industry and the company's reputation.

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies